key: cord-0848472-uvg44xvl
authors: El-Ansary, Afaf; Balto, Hanan; Al-Hadlaq, Solaiman M.
title: Gut-lung cross talk in COVID-19 pathology and fatality rate
date: 2022-01-14
journal: Data Science for COVID-19
DOI: 10.1016/b978-0-323-90769-9.00037-2
sha: 5210c13445e19d3d7dcd0352b0e18c6d526b93b1
doc_id: 848472
cord_uid: uvg44xvl

Coronavirus disease 2019 (COVID-19) is the leading pandemic facing the world in 2019/2020; it is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which necessitates clear understanding of the infectious agent. The virus manifests aggressive behavior with severe clinical presentation and high mortality rate, especially among the elderly and patients living with chronic diseases. In the recent years, the role of gut microbiota, in health and disease, has been progressively studied and highlighted. It is through gut microbiota-organ bidirectional pathways, such as gut-brain axis, gut-liver axis, and gut-lung axis, that the role of gut microbiota in prompting lung disease, among other diseases, has been proposed and accepted. It is also known that respiratory viral infections, such as COVID-19, induce alterations in the gut microbiota, which can influence immunity. Based on the fact that gut microbiota diversity is decreased in old age and in patients with certain chronic diseases, which constitute two of the primary fatality groups in COVID-19 infections, it can be assumed that the gut microbiota may play a role in COVID-19 pathology and fatality rate. Improving gut microbiota diversity through personalized nutrition and supplementation with prebiotics/probiotics will mend the immunity of the body and hence could be one of the prophylactic strategies by which the impact of COVID-19 can be minimized in the elderly and immunocompromised patients. In this chapter, the role of dysbiosis in COVID-19 will be clarified and the possibility of using co-supplementation of personalized prebiotics/probiotics with current therapies will be discussed.

bowel and the lungs is the penetration of chronic inflammatory cells and the response of interstitial cells. Studies of gut microbiota have shown that microbiota could provide essential health benefits to the host by regulating immune homeostasis [10] .

Chronic lung syndromes, such as chronic obstructive pulmonary disease, cystic fibrosis, and asthma, display signs of intestinal dysfunction [11e13] . In addition, respiratory viral infections frequently demonstrate concomitant intestinal dysfunction [14, 15] . It has also been shown that alterations in the gut microenvironment are usually reported during the development of various lung diseases. Among these alterations is the shift in the composition of the gut bacteria or microbiota [16e18] .

It is well accepted that probiotics can minimize antibiotic-associated dysbiosis and infections not only in the gastrointestinal tract but also in other body sites, including in respiratory tract infections (RTIs) [19, 20] . Probiotics are generally safe and noninvasive, even in the most susceptible populations including intensive-care patients [21] . The use of probiotics, prebiotics, and synbiotics could produce protective effects against external environmental viral infections through the buildup of internal defenses by boosting the immune system. In the case of coronavirus disease 2019 (COVID- 19) pandemic, this might result in reduced infection rates, lessened systemic inflammatory responses, shorter intensive-care stays and mechanical ventilation duration, and lower fatality [21] .

The evidence is highly suggestive of a dynamic cross talk between the gut and the lungs as two mucosa covered parts of the human body. In this chapter, we discuss the changes in the gut microbial composition associated with lung disease and the impact of altered gut microbiota on healthy and COVID-19-infected lungs, together with the possibility of using probiotic co-supplementation with current therapies as a protective strategy in COVID-19 patients, which might help flatten the curve of infection.

The human body is normally colonized by trillions of bacteria in different compartments of the body. Among these compartments are the oral cavity, the gut, and the respiratory tract [9e16]. The colonizing bacteria are usually from six different phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and Cyanobacteria [22e28]. However, the relative abundance and diversity of these phyla, especially the bacterial composition at the genera level, vary considerably between different body compartments [29] .

A healthy adult's gut microbiome is an extraordinarily stable microbial community composed of highly adapted microbial species [30] that are affected by the environment as well as the host genetics [31] . While high microbiota diversity appears to be associated with health, a dynamic loss of diversity may be prognostic of increased disease risk [32, 33] . A physically inactive lifestyle and the consumption of a diet that is high in refined carbohydrates and salt and low in dietary fibers [34, 35] are connected to the depletion of healthy gut microbiota and increased prevalence of chronic diseases [36] .

Dysbiosis of the gut microbiota has been associated with a variety of local and systemic chronic disorders, highlighting the importance of a balanced microbial community in the gut for proper immune function and health [37, 38] . Keeping a balanced gut microbiota, or restoring an altered gut flora, can be accomplished through different strategies, among which are probiotics, fecal microbiota transplantation (FMT), or live biotherapeutics. This may help in the development of a healthy and functional gut microbiota, a normal immune response, and healthy organs through multiple gut microbiota, brain, liver, and retina axis [1, 39] (see Fig. 3 .1).

Recently, with the introduction of the culture-independent procedures for microbiologic examinations, which are based on RNA/DNA sequencing or microarrays, many studies indicated that, in addition to the upper respiratory tract, the lower respiratory tract, i.e., the lungs, is populated by various types of microbiota [40, 41] . However, the lower respiratory tract is one of the least colonized by bacteria among compartments of the human body. In a marked similarity to the gut, the two predominant phyla identified in the respiratory tract are Firmicutes and Bacteroidetes, whereas Actinobacteria, Proteobacteria, and Fusobacteria are minor constituents of the respiratory tract microbiota [23, 25] . The "core microbiota" of healthy individuals consists mainly of the following genera: Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Veillonella, Haemophilus, Neisseria, and Porphyromonas [42, 43] . A study provided evidence indicating that gut and lung microbiota develop simultaneously and that there is a constant cross talk between these two compartments [44] .

It has been shown that bacteria appear in the gut earlier than their identification in the airway [44] , providing suggestive evidence for the involvement of microaspiration of gut microbes in the development of the lung microbiota. Factors such as diet have also been shown to affect the composition of the gut and lung microbiota [44, 45] . The diversity of lung microbiota is mostly affected by three factors: the type and number of microbiota arriving into the lungs, removal of microbes from the lungs, and replication rates of the microbe itself in the lungs [43, 46] .

Based on the recently highlighted role of gut microbiota in health and diseases, it is essential to clarify the role of gut-lung cross talk in the etiopathology of lung disease [47] . The cross talk between gut microbiota and lungs, known as the gut-lung axis, is critically important for the homeostasis and immune response of the respiratory system. Certain gut microbiota-associated strategies have been approved to treat and prevent lung diseases [1] . Ichinohe et al. [48] suggested that gut microbiota play a critical role in the generation of virus-specific CD4 þ and CD8 þ T cells and antibody responses after a respiratory influenza virus infection. Multiple studies have shown that alterations in the gut bacterial species and metabolites were associated with abnormal immune responses, inflammation, and lung disease severity. Altered gut microbiota composition can be related to lung disease through the gut-lung axis. Regulatory T-cell (Treg) subsets, tolllike receptors (TLRs), inflammatory cytokines, surfactant protein D, and several other factors have been postulated as contributors to the causal mechanisms [49e54].

The effect of gut microbiota alterations on respiratory viral infections has been studied in the recent years [55e57]. Reduction in the diversity of the gastrointestinal tract microbiota was followed by a considerable increase in mortality due to respiratory viral infections. This increase in mortality due to respiratory viral infections was associated with a defective immune response characterized by increased lung interferon (IFN)-g, interleukin (IL)-6, and CCL2 and decreased count of Tregs in the lungs. Neutralization of IFN-g or adoptive transfer of Tregs significantly combated the increased mortality [58] . Viral lung infections are also associated with an increase in colonic Muc5ac levels and fecal lipocalin-2, indicating low-grade inflammation in the gut ( Fig. 3. 2) [59] .

Some patients with COVID-19 presented with dysbiosis of gut microbiota with decreased healthy bacteria or probiotics such as Lactobacillus and Bifidobacterium. Based on this finding, nutritional and gastrointestinal functions should be evaluated for all patients. Nutritional intervention through the use of prebiotics or probiotics is encouraged to regulate the balance of intestinal microbiota and thus reduce the risk of secondary infections due to bacterial translocation. Regular followeup of fecal microbiota in patients during the 2-week quarantine is recommended and might help avoid secondary bacterial infection [60] . A study by Yu et al. [61] reported the dynamic structure of the host immune system and the gut microbiota imbalance in three critical care patients with COVID-19. Hypoxemia severity was correlated to the vicious circle between immune deficiency and gut microbiota imbalance and was suggested as a contributor to the high risk of fatal pneumonia.

On the other hand, several probiotics have been shown to prevent and/or decrease the length of viral infections. Most of the studies supporting the effectiveness of immune system reinforcement by using probiotics have been validated in animal models. In mice, intranasal injection of Lactobacillus reuteri or Lactobacillus plantarum have displayed a protective potential against lethal viral pneumonia [62] .

The mechanism by which gut microbiota protect the lungs from S. aureus infection has been explored. Gut microbiota disruption caused by antibiotics decreased pulmonary resistance to S. aureus due to impaired TLR4 function [54] . Qin et al. [63] reported that severe COVID-19 cases have lower lymphocyte counts, higher leukocyte counts, and higher neutrophil/lymphocyte-ratio, as well as elevated levels of inflammatory cytokines. They also demonstrate much lower numbers of helper T cells and suppressor T cells. The percentage of naive helper T cells was increased and that of memory helper T cells was decreased in severe cases. Patients with COVID-19 also have lower levels of Treg cells that is correlated with the severity of the case. Thus these markers might help in the early diagnosis and, thereby, better management of novel Coronavirus infections.

Extensive, and frequently improper, use of antibiotics may lead to the increase in bacterial resistance and disruption of the normal balance of human microbiota, thereby assisting pathogenic bacteria colonization [64, 65] . Probiotics are defined by the World Health Organization as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [66] . The most commonly used probiotics are Lactobacillus and Bifidobacterium species, followed by the genera Propionibacterium, Bacillus, Streptococcus, Enterococcus, and Escherichia coli [67] . In addition, some yeast species are used as probiotics; for example, Saccharomyces boulardii and Saccharomyces cerevisiae are repeatedly used to treat gastrointestinal disorders [68, 69] . A well-characterized probiotic should be defined clearly by the genus, species, and strain description, as well as specify the bacteriologic culture conditions [68] . Probiotic-containing products may be supplied as capsules, tablets, and most commonly as powders, as well as food ingredients [70] . Probiotics may exert a wide range of favorable effects, such as balancing the host gut microbiota and strengthening the innate and adaptive immune system, which may stimulate the development of resistance against pathogens [71] . It must be stated that probable major mechanisms of probiotic effects on RTIs are yet to be clearly defined. Besides the local effect of competitively inhabiting the gut to eliminate pathogenic bacterial species, controlling the gut barrier utility and permeability, probiotics have been shown to demonstrate numerous host immunomodulatory effects [72e74]. It has been shown that probiotics can influence both innate and adaptive immune responses by producing exopolysaccharides [75] . In addition, probiotics could increase leukocyte, neutrophil, and natural killer cell counts and activity [19] . They are also able to increase the expression of IL-10 and decrease inflammatory cytokine expression, such as tumor necrosis factor a, IL-1b, and IL-8 [76] . Furthermore, probiotics can maintain higher levels of salivary immunoglobulin A and produce bacteriocins and reuterin, which have antimicrobial activity [77] (see Fig. 3.3) .

Data generated through a meta-analysis of 23 randomized clinical trials proposed that probiotic feeding may decrease the prevalence and disease duration of RTI episodes.

It is essential to observe, in future clinical trials, the optimum probiotic strain(s), dosing, type of formulation, and time of intervention as well as implement an appropriate follow-up protocol [78] .

Clinically used probiotics have been classified as monostrain or multistrain products, with multistrain/multispecies products being more beneficial because of the expected symbiosis among strains [79] . In addition to orally supplemented probiotics, fecal transplant can be used as another strategy of probiotic microbial intervention. Fecal microbial transplantation (FMT) denotes to the process of transferring gut microbiota from a healthy individual to a dysbiotic patient with unbalanced gut microbiota in an attempt to restore normal diversity of gut microbiota [80, 81] . It is based on the rationale that manipulation of the microbiome could prove potentially therapeutic for disease states with an altered microbial composition.

A meta-analysis of clinical trials, involving more than 10,000 individuals, demonstrated that synbiotic (mixture of probiotic and prebiotic) interventions could be an alternative nutritional strategy for conferring human health and preventing RTIs. Future investigations on the clinical efficacy and safety of synbiotic interventions are necessary, with special attention to strain-specific and dose-specific measures [82] . A probiotic Bifidobacterium longum 5(1A) was able to protect mice against lung infection caused by Klebsiella pneumoniae. It induced faster resolution of inflammation by increased production of IL-10 and decreased lung injury with significant decrease in the burden of secondary bacterial infection. The underlying mechanism is partly attributed to the activation of the TLR adapter protein [83] .

Probiotics were able to produce a considerable reduction in the frequency of upper RTI in preschool Malaysian children. In a 10-month randomized, double-blind, parallel, placebo-controlled study, the effects of B. longum BB536 probiotic on upper RTI and diarrhea in 219 subjects (110 placebo and 109 BB536 supplemented) were evaluated [84] . While BB536 probiotic supplement did not exert significant effects against diarrhea in children, it was effective in reducing sore throat duration by 46%, fever by 27%, runny nose by 15%, and cough by 16% when compared to the placebo. Additionally, the probiotic-treated group demonstrates much higher abundance of the genus Faecalibacterium known to exert anti-inflammatory and immunomodulatory properties. Overall, the BB536 probiotic imparts protective effects against upper respiratory illnesses as well as beneficial gut microbiota modulating properties.

The effectiveness of using synbiotics in treating RTIs was reported to be a more potent preventive measure among adults than infants and children [85] .

Using mice as a model system in microbiota research is still considered a powerful tool. In a rodent model, the microbiota can be examined under controlled conditions such as homogenous genetic background, diet consumption, and housing factors [86] . Feeding mice with probiotic Lactobacillus paracasei CNCM I-1518 strain resulted in reduced vulnerability to the influenza infection, concomitant with less accumulation of inflammatory cells in the lungs, earlier viral clearance, and overall improved health. Interestingly, Allobaculum (bacterial genus), known to be positively correlated with IL-17 expression, was significantly increased in L. paracasei-fed mice 7 days after influenza infection, even if the gut microbiota composition was not altered overall. L. paracaseipurified peptidoglycans partially represent the protective phenotype observed with L. paracasei [87, 88] .

It is well accepted that, when antibiotics are used, strengthening of gut microbiota by using probiotics will lessen the vulnerability to secondary infections as commonly happens in COVID-19 patients. In addition to the effectiveness of probiotics in treating RTIs, they are proposed to have a direct effect on SARS-CoV-2 or COVID-19. In fact, in line with the gut-lung cross talk, which has been anticipated to play a critical role in COVID-19 pathogenesis, controlled randomized trials showed that critically ill patients on mechanical ventilation who were given probiotics (Lactobacillus rhamnosus GG, live Bacillus subtilis, and Enterococcus faecalis) developed substantially less ventilatorassociated pneumonia (VAP) compared with placebo [9, 89, 90] . This finding might contribute significantly to reducing the fatality rate of COVID-19 pandemic.

Chinese COVID-19 patients demonstrated microbial dysbiosis with diminished Lactobacillus and Bifidobacterium gut flora as a comorbidity in COVID-19 [60] . Lactobacilli and Bifidobacteria are the only two types of beneficial bacteria that were accepted for combating COVID-19 through the restoration of healthy gut microbiota. Random use of conventional probiotics for COVID-19 management is not recommended until a clear understanding of the pathogenesis of SARS-CoV-2 and its effect on gut microbiota is attained. It is likely that a novel and more precise targeted approach to the modulation of gut microbiota will be accepted as one of the therapeutic mechanisms to combat COVID-19 and its comorbidities [89] .

The use of probiotics is an interesting emerging field in oral healthcare. Probiotics are defined as living microbial agents of human origin able to tolerate the hostile gastrointestinal environment to confer health benefits on the host when used in an adequate amount [66] . Probiotics have several positive effects on the health of the host, such as reduced constipation, decreased blood cholesterol levels, and improved lactose tolerance and calcium intake [91] . Probiotic bacteria consist of two main groups, namely, Lactobacillus and Bifidobacterium. Lactobacillus, as a member of oral microbial flora, can play an important role in the microcosm balance of the oral cavity. On the other hand, less information is available about the useful role of Bifidobacterium in the health of the oral cavity [92] .

The widespread oral intake of probiotics as preventive and therapeutic products for gastrointestinal health makes them of considerable interest for oral healthcare workers [93] . Probiotics are recognized as a potent therapeutic agent for dental caries, periodontal disease, and halitosis. The oral cavity is a habitat for a diverse population of microorganisms that is responsible for influencing oral health and disease. Although resident oral microorganisms are typically in homeostasis with the host, a disturbance in the balance (e.g., decrease in oral pH, presence of high levels of dietary carbohydrates, and poor oral hygiene) can initiate and potentiate oral diseases such as dental caries, periodontitis, and gingivitis [94, 95] .

Studies have presented possible mechanisms behind the positive effect of probiotics on caries and dental plaque. Probiotics compete with pathogenic bacteria that adhere to the mucosa and tooth structure causing their displacement [96, 97] ; they produce hydrogen peroxide, lactic acid, and bacteriocin as antibacterial agents against oral pathogens [98e101]; they change the acidity of the oral environment by reducing the pH and thereby prevent the growth of bacteria [102] ; and they stimulate nonspecific immunity and regulate cellular and humoral immune responses [103] . Probiotics also act as antioxidants and prevent plaque formation by neutralizing free electrons [104] .

Although probiotic research in the field of dental sciences is relatively new, preliminary evidence suggests their beneficial influence on maintaining oral health. A literature review concluded that a potent probiotic helps prevent and reduce the risk of caries development in children and adults. Lactobacillus and Streptococcus species were examined for their anticariogenic potential in most of the studies [105] . Other studies suggested that consumption of products containing probiotic lactobacilli or bifidobacteria can reduce the number of Streptococcus mutans in saliva and therefore could have a preventive effect on the development of dental caries [92,106e108] . On the other hand, Gruner et al. [109] evaluated the influence of probiotic therapy with lactobacilli on periodontal pathogen counts and concluded that the current evidence is insufficient for recommending probiotics for managing dental caries, but supportive toward managing gingivitis or periodontitis. Probiotics lower the pH of the oral cavity and prevent the formation of dental plaque and calculus that causes periodontal disease [110] . In addition, probiotics produce antioxidants that interfere with plaque formation by neutralizing the free electrons needed for mineral formation [111] . Probiotic mouthwash formulation was evaluated as an alternative to traditional mouthwash for the prevention of periodontal disease. It demonstrated a significant decrease in the plaque index and gingival index compared to placebo [112] and to chlorhexidine (CHX) [113e115] .

Regular use of probiotics can also help control halitosis. The common organisms involved in halitosis are Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, and Treponema denticola. These organisms degrade amino acids that are in turn transformed into volatile sulfur compounds causing halitosis. The use of Weissella cibaria as a mouthwash resulted in reduced levels of volatile sulfide components produced by F. nucleatum through the release of hydrogen peroxide and bacteriocin by W. cibaria that inhibited the proliferation of F. nucleatum [116] . Streptococcus salivarius also suppresses volatile sulfide compounds by competing for colonization areas with volatile sulfide-producing species [117] .

VAP continues to be one of the most prevalent and serious complications during ventilation. Because of the high morbidity and mortality rate in VAP, pharmacologic and nonpharmacologic interventions aimed at VAP prevention have been proposed, including administration of antibiotics, selective digestive tract decontamination, CHX mouthwash, subglottic secretion drainage, elevation of the head of the bed, and other preventive measures [118e120]. Decontamination with antibiotics reduces the incidence of VAP [121] , but it is not currently recommended due to the risk of development of resistant bacteria. Oropharyngeal rinse with CHX has been shown to be effective in reducing tracheal colonization and VAP incidence [122e124]; however, it does not influence the survival rate [122, 124] . Nevertheless, similar to antibiotics, CHX induces bacterial resistance and hypersensitivity [125e127] . Although the effect of probiotics in VAP is still uncertain, several advantages such as low cost, ease of administration, and minimal toxicity make them a promising approach to prevent RTIs. Probiotics have been initially used as a potential adjunctive treatment for VAP prevention [128] . Later, some evidence emerged suggesting using it as a feasible and safe agent for oral care in critically ill patients to reduce pathogens in the oropharynx [129e134], while others failed to show any evidence to support reduction of ICU or hospital mortality by the administration of probiotics [132,135e137] . Probiotics could potentially reduce the incidence of pneumonia in critically ill patients by reducing the overgrowth of pathogenic microorganisms, enhancing gut barrier function, reducing bacterial translocation, and upregulation of immune functions [103,138e143] . The effect of probiotics on VAP prevention is a controversial issue because the availability of high-quality randomized control trials is limited and their results are inconsistent [90,131,134,144e147] .

The use of probiotics is an interesting emerging field in oral healthcare. Based on the currently available clinical data, it seems that dietary probiotics do not induce a major risk for oral health. Therefore probiotic therapy can be considered as a natural and noninvasive way to prevent tracheal colonization with pathogenic bacteria and reduce the risk of aspiration of contaminated secretions. However, high-quality randomized clinical trials with long-term follow-up are needed to confirm the clinical benefit of probiotics in critically ill patients.

Gut microbiota and lung injury

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Advances in Virus Research

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

World Health Organization, WHO Director-General's Remarks at the Media Briefing on

WHO declares COVID-19 a pandemic

Clinical features of deaths in the novel coronavirus epidemic in China

Understanding the viscera-related theory that the lung and large intestine are exterior-interiorly related

Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial

Microbiota-stimulated immune mechanisms to maintain gut homeostasis

Acute intestinal obstruction as a presentation of cystic fibrosis in infancy

Lung-gut cross talk: a potential mechanism for intestinal dysfunction in patients with COPD

Increased prevalence of irritable bowel syndrome in patients with bronchial asthma

Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness

Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 celledependent inflammation

Low gut microbiota diversity in early infancy precedes asthma at school age

Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age

Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial

Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial

Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children e a 2019 update

Probiotic and synbiotic therapy in the critically ill: state of the art

Diversity of the human intestinal microbial flora

Analysis of the lung microbiome in the "healthy" smoker and in COPD

The human nasal microbiota and Staphylococcus aureus carriage

Disordered microbial communities in asthmatic airways

Heterogeneity of vaginal microbial communities within individuals

Metagenomic study of the oral microbiota by Illumina high-throughput sequencing

Structure of the human gastric bacterial community in relation to Helicobacter pylori status

The human microbiome: at the interface of health and disease

Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation

Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity

The healthy human microbiome

Prebiotics in healthy infants and children for prevention of acute infectious diseases: a systematic review and meta-analysis

Prü ss-Ustü n, Climate change, air pollution and noncommunicable diseases

Globalization of diets and risk of noncommunicable diseases, in: The Role of Functional Food Security in Global Health

Links between environment, diet, and the hunter-gatherer microbiome

Disbiome database: linking the microbiome to disease

Establishing what constitutes a healthy human gut microbiome: state of the science, regulatory considerations, and future directions

The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood

The microbiome and the respiratory tract

The microbiota of the respiratory tract: gatekeeper to respiratory health

Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant

Topographical continuity of bacterial populations in the healthy human respiratory tract

Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures

Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis

Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals

Emerging pathogenic links between microbiota and the gutelung axis

Microbiota regulates immune defense against respiratory tract influenza A virus infection

Microbiota in T-cell homeostasis and inflammatory diseases

The role of gut microbiota in atopic asthma and allergy, implications in the understanding of disease pathogenesis

miR-182-5p contributes to intestinal injury in a murine model of Staphylococcus aureus pneumonia-induced sepsis via targeting surfactant protein D

Surfactant proteins SP-A and SP-D ameliorate pneumonia severity and intestinal injury in a murine model of Staphylococcus aureus pneumonia

The lung microbiome, immunity, and the pathogenesis of chronic lung disease

TLR4 deficiency reduces pulmonary resistance to Streptococcus pneumoniae in gut microbiota-disrupted mice

Interactions between enteric bacteria and eukaryotic viruses impact the outcome of infection

Respiratory viral infection-induced Microbiome alterations and secondary bacterial pneumonia

The commensal microbiota and viral infection: a comprehensive review

Intestinal microbiota disruption reduces regulatory T cells and increases respiratory viral infection mortality through increased IFNg production

Respiratory disease following viral lung infection alters the murine gut microbiota

Management of corona virus disease-19 (COVID-19): the Zhejiang experience

Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease

Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Effects of antibiotics on gut microbiota

Interventions to influence consulting and antibiotic use for acute respiratory tract infections in children: a systematic review and meta-analysis

Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food

Probiotic bacterial and fungal strains: claims with evidence

World gastroenterology organisation global guidelines: probiotics and prebiotics

Probiotics for the treatment of infantile colic: a systematic review

An update on the use and investigation of probiotics in health and disease

Probiotics in neonatology

Effect of lactobacilli on paracellular permeability in the gut

The role of probiotics and prebiotics in pediatric practice

Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans

Genomic overview and biological functions of exopolysaccharide biosynthesis in Bifidobacterium spp

Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis

Probiotics as modulators of the gut flora

Probiotics for prevention and treatment of respiratory tract infections in children: a systematic review and meta-analysis of randomized controlled trials

Monostrain, multistrain and multispecies probioticsda comparison of functionality and efficacy

Microbiota replacement therapies: innovation in gastrointestinal care

Fecal microbiota transplantation

Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate

Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 51A

Double Blind, Placebo-Controlled Study on the Efficacy of Bifidobacterium longum Bb536 in Reducing Symptoms of Respiratory and Gastrointestinal Diseases Among Young Children

Preventing respiratory tract infections by synbiotic interventions: a systematic review and meta-analysis of randomized controlled trials

How informative is the mouse for human gut microbiota research?

Lactobacillus paracasei feeding improves immune control of influenza infection in mice

Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences

Probiotics and COVID-19: one size does not fit all

Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial

A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children

Probiotics: contributions to oral health

Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations

Dental plaque as a biofilm and a microbial communityeimplications for health and disease, in: BMC Oral Health

Microbial ecology of dental plaque and its significance in health and disease

Oral microbial habitat a dynamic entity

An assessment of adhesion, aggregation and surface charges of Lactobacillus strains derived from the human oral cavity

Modulation of host responses by oral commensal bacteria

The use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease

Are we ready for caries prevention through bacteriotherapy?

Probiotics for caries prevention and control

Acid production from sugars and sugar alcohols by probiotic lactobacilli and bifidobacteria in vitro

Probiotics: effects on immunity

Probiotics-do they have a role in medicine and dentistry

A review of the role of probiotic supplementation in dental caries

Shortterm consumption of probiotic-containing cheese and its effect on dental caries risk factors

Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets

Effect of longeterm consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children

Probiotics for managing caries and periodontitis: systematic review and meta-analysis

Benefits of live microorganisms (Probiotics) in periodontal health

Probiotics in dentistry: a boon or sham

The Effect of probiotic mouthrinse on plaque and gingival inflammation

Efficacy of a probiotic and chlorhexidine mouth rinses: a short-term clinical study

Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, doubleblind, placebo-controlled study

Effect of probiotic mouthrinse on dental plaque accumulation: a randomized controlled trial

Inhibitory effect of Weissella cibaria isolates on the production of volatile sulphur compounds

A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters

Advances in the prevention and management of ventilator-associated pneumonia

Evidence on measures for the prevention of ventilator-associated pneumonia

Diagnosis, management and prevention of ventilator-associated pneumonia

Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study

Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia

Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia

Oral care with chlorhexidine seems effective for reducing the incidence of ventilator-associated pneumonia

Chlorhexidine allergy: sources of exposure in the healthcare setting

Chlorhexidine and hypersensitivity reactions in dentistry

Chlorhexidine-induced anaphylaxis in surgical patients: a review of the literature

Probiotic manipulation of the native flora in critically ill patients: an opportunity for ventilator-associated pneumonia prophylaxis

Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials

Probiotics for preventing ventilatorassociated pneumonia

Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study

Probiotics' effects on the incidence of nosocomial pneumonia in critically ill patients: a systematic review and meta-analysis

Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis

Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality

Can probiotics be an alternative to chlorhexidine for oral care in the mechanically ventilated patient? A multicentre, prospective, randomised controlled open trial

C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia

Probiotics for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of high-quality randomized controlled trials

Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial

Probiotics and lung diseases

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis

Mechanisms of action of probiotics

Administration of probiotics reduces bacterial translocation after intestinal transplantation in rats

Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial

Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients

Improvement of nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented milk containing probiotic Lactobacillus johnsonii La1 (NCC533)

Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials